Yesterday’s movers set for big range again

Traders piling into these names                                                                                                                                                                                                                                                                                                                                                                                                                 [header] *Together with A “HUGE” BREAKOUT OPPORTUNITY (NASDAQ: HUGE) Good day, 360 – Here are our top investing ideas today – these setups look primed! Be the best prepared trader on the Street! [focus list] GFAI - 2nd day play, closed up over 88% after breakout above resistance NCMI - Closed up over 114% yesterday on AMC taking a stake in the company, gapping 19% higher this morning IDAI - Closed up 100% yesterday after announcing 3 new U.S patents related to its AI-based biometric authentication technology *A Message on Behalf of FSD Pharma 🔥Hot Stock of the Day 🔥 On Monday, we shared with you a new featured stock – FSD Pharma (Nasdaq: HUGE). We wanted to update you on how things have been going so far… because, frankly, it has been a “HUGE” move higher! While the markets have been trending lower, HUGE has managed to make a brand-new 52-week high each day since then. 📈 It has gained over 17% in just the last 3 days! (I wonder what is coming next for this stock? 🤔) A big part of this could be that one of the original Sharks🦈 on Shark Tank, Kevin Harrington, [posted]( that he is excited to be working with FSD Pharma (Nasdaq: HUGE) on an upcoming “breakthrough new product” that could be an absolute gamechanger. We are in the early stages of something that could be truly revolutionary right now. (Nasdaq: HUGE) is already up over 100% so far this year as investors are learning more about the opportunity at hand… and we could just be getting started! Remember, (Nasdaq: HUGE) has a perfect “100% BUY” rating on [Barchart]( right now, and that just about says it all when it comes to the technicals for the price chart right now. There is a lot to love about FSD Pharma (Nasdaq: HUGE) right now, so do your own homework on it, and see if this stock should have a place in your portfolio today! *Sponsored by FSD Pharma. Please see disclosures below. [hotlist] GFAI - 2nd day play, closed up over 88% after breakout above resistance We mentioned GFAI as a stock to watch on Monday. Yesterday it continued its strength breaking out of its cup and handle/reverse head and shoulders pattern on the daily timeframe. Artificial Intelligence stocks are still in play as we’ve seen with LUCY and IDAI as well this week. $28.50 was a resistance level yesterday and is an important level to watch today. Above it, targets to the upside are $30, $31.08, $31.79 and yesterday’s high of $34.85. Beyond that, $44.80 and $50 come into play. Below $28.50, there is potential support at $25.50, $24.50, $23.50, $22.80 and then $21.50. $20 would be the next target below that and then $17. NCMI - Closed up over 114% yesterday on AMC taking a stake in the company, gapping 19% higher this morning National CineMedia (NCMI) continues its momentum higher after announcing that AMC was taking a 9.1% passive stake and that it would be conducting a series of debt restructuring. The stock was trading above $2 last year. $0.50 acted as a resistance level yesterday and support in the pre-market this morning and is an important pivot level moving forward. Above it, targets to the upside are $0.55. $0.57, with $0.62 and $0.6490 above that. Beyond that, $0.68, $0.80, $0.90 and $1 would be the major targets to the upside. Below $0.50, there is potential support at $0.47, $0.45, $0.4150, and $0.36, with $0.32 and $0.29 below that. IDAI - Closed up 100% yesterday after announcing 3 new U.S patents related to its AI-based biometric authentication technology T Stamp (IDAI) was the AI PR stock de jour yesterday. Be on the lookout for these in the pre-market as we’ve seen some big moves continue this week. The $3.30 area was support in the after-hours yesterday and again in pre-market this morning and will be an important level to watch. Above it, targets to the upsidea are $3.65, $4.10, $4.50, $4.75 and the pre-market high of $4.85 above that. Beyond that, $5.20, $6 and $8 come into play. Below $3.30, there is potential support at $2.60, $2.20 and $2 below that. Economic Calendar (EST) 8:30am PPI Final demand 8:30am Jobless claims 10:30am EIA Nat Gas report No Fed Speakers Scheduled Earnings for Today (After Market) LAKE, WAFD Top Headlines UPS to negotiate with teamsters on national master agreement. OXY Occidental sees its output higher in 10 years versus today – Bloomberg GNS Genius Group Changes Extraordinary General Meeting Date for Entrepreneur Resorts Spinoff to May 16 PLXP PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets GCTK GlucoTrack Announces Proposed Underwritten Public Offering of Common Stock CWT California Water Service Receives $4.3 Million Grant From Department of Water Resources To Connect Struggling, Disadvantaged Water Systems to Its Salinas System IMPP: Imperial Petroleum Inc. Announces Proposed Spin-Off of Two of Its Drybulk Carriers MRK: FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma ATAI atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine) ALTR: U.S. Court of Appeals for the Federal Circuit Affirms Dismissal of Lawsuit Initiated by SAS Institute against Altair (World Programming) for Alleged Copyright Infringement BLCO Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma™ Fully Digital Surgical Visualization Platform DNA Ginkgo Bioworks and WARF Announce Partnership to Discover Next Generation GD2 CAR T-Cell Therapies ALDX: Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis TNXP: Tonix Pharmaceuticals Expedites Fibromyalgia and Chronic Migraine Programs SSYS: Stratasys Board of Directors Unanimously Rejects the Nano Dimension Revised Unsolicited Proposal of $20.05 Per Share DTIL: Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease INTC Germany Urges Intel to Increase Investment in €17 Billion Chip Manufacturing Facility - Financial Times SRPT: Volatility -- STAT News .. FDA staff leaned toward rejecting Sarepta gene therapy before top official intervened CYBR Barclays Maintains Overweight on CyberArk Software, Raises Price Target to $175 from $158 TSLA Twitter Partners with e Toro to Allow Crypto and Stock Trading on Twitter starting Thursday. Elon Musk told a Morgan Stanley conference last month he wants Twitter to become "the biggest financial institution in the world." LTRN: Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284 SNDL: SNDL Announces Filing of Annual Report by April 24 and Provides Bi-Weekly MCTO Status Update OPEC Data Show Oil Cuts Will Cause Widening Supply Shortfall - World Oil Demand To Rise By 2.32 Million BPD In 2023 (Unchanged From Prev. Forecast) – Monthly Report - China’s Oil Demand To Rise By 760,000 BPD In 2023 (Up From 710,000 BPD Prev. Forecast) HBM Hudbay and Copper Mountain Combine to Create a Premier Americas-Focused Copper Producer OCEA Ocean Biomedical's Co-Founder Expects To Receive US Patent Covering Malaria Therapeutics - Ocean Biomedical sm NXPL NextPlat Announces Completion of $6.0M Private Offering of Common Stock Priced Above Market SQNS: SKYFive, Flightcell, and Sequans Introduce the World's Smallest Airborne Terminal for Air-to-Ground Communications WIMI: WiMi Develops a 3D Object Recognition System Based on Multi-View Feature Fusion DM Aidro Achieves Industry-First Global Additive Manufacturing Facility Certification from DNV for Metal 3D Printing with Two Technologies TWST: Twist Bioscience Launches TCR and CAR Libraries to Enable the Development of Cell Therapies To Your Success! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions *PAID ADVERTISEMENT. RagingBull has been paid fifteen thousand dollars by ach bank transfer by FSD Pharma for advertising from a period beginning on April 10 , 2023 through April 14 of the same year. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull, do not hold a position in FSD Pharma. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of FSD Pharma, increased trading volume, and possibly an increased share price of the FSD Pharma securities, which may or may not be temporary and decrease once the marketing arrangement has ended. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. [tw]( Update your email preferences or unsubscribe [here]( © 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States [[beehiiv logo]Powered by beehiiv](